drugset / Trial / NCT05006898

Compound to Control Presbyopia Symptoms

NCT05006898

Phase 1 Completed 11 enrolled Optall Vision
RandomizedParallel-groupDouble-blindTreatment

Summary

Low dose compose to control presbyopia symptoms

Timeline

Start
2020-06-01
Primary completion
2020-07-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule Other
Subject Oxymetazoline Other / unclassified Other
Subject Pilocarpine Unknown Other

Indications